Roche's Lunsumio Meets Primary Endpoint in Earlier-Line Follicular Lymphoma
A confirmatory phase 3 trial showed Roche's T-cell engager Lunsumio achieved its primary endpoint in earlier-line follicular lymphoma.
Roche has reported a positive confirmatory trial readout for Lunsumio, a T-cell engaging bispecific antibody. The phase 3 study met its primary endpoint in earlier-line follicular lymphoma, according to a report from Fierce Pharma. No specific efficacy numbers or effect sizes were disclosed in the source.
The result marks the latest milestone for Roche's T-cell engager portfolio, which has been expanding across blood cancers. Because the source provides only this single trial update, there is no comparative data from other studies or competing therapies to weigh against the finding.
Lunsumio is already an established option in relapsed or refractory settings, and this earlier-line readout suggests it could move into a less advanced stage of treatment. Full results and regulatory implications are likely to follow in future presentations.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.